In pre-BCR + ALL, genes with abnormally high expression such as VPREB1, IGLL1, SYK, PRKCZ, BLNK, BLK, ZAP70, BACH2, TCF3 and POU2AF1 were down-regulated after treatment; while genes that were repressed due to aberrant pre-BCR activation, such as IL2RA(CD25), IL13RA1, CD34, ID2, CD69, CD99, ITGA6, CCND2, SOCS2, PRDM1, TLE3, and EMP1 genes were up-regulated by CUDC-907 (Fig. 5i). The gene discussed is BLNK; the disease is acute lymphoblastic leukemia.